Inogen Inc (INGN)

$7.09

+0.14

(+2.01%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Inogen Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 83.96M → 75.89M (in $), with an average decrease of 9.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -45.71M → -26.55M (in $), with an average increase of 72.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 77.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 155.5%

Performance

  • $6.79
    $7.20
    $7.09
    downward going graph

    4.23%

    Downside

    Day's Volatility :5.69%

    Upside

    1.53%

    downward going graph
  • $4.13
    $14.10
    $7.09
    downward going graph

    41.75%

    Downside

    52 Weeks Volatility :70.71%

    Upside

    49.72%

    downward going graph

Returns

PeriodInogen IncSector (Health Care)Index (Russel 2000)
3 Months
30.52%
-0.7%
0.0%
6 Months
48.5%
6.6%
0.0%
1 Year
-45.28%
3.7%
-1.5%
3 Years
-88.94%
14.0%
-21.8%

Highlights

Market Capitalization
161.7M
Book Value
$8.78
Earnings Per Share (EPS)
-4.42
PEG Ratio
3.48
Wall Street Target Price
6.5
Profit Margin
-32.46%
Operating Margin TTM
-28.63%
Return On Assets TTM
-10.91%
Return On Equity TTM
-40.8%
Revenue TTM
315.7M
Revenue Per Share TTM
13.62
Quarterly Revenue Growth YOY
-13.8%
Gross Profit TTM
153.5M
EBITDA
-45.7M
Diluted Eps TTM
-4.42
Quarterly Earnings Growth YOY
0.87
EPS Estimate Current Year
-2.5
EPS Estimate Next Year
-1.96
EPS Estimate Current Quarter
-0.62
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Hold
    0
    0%Buy
    55%Hold
    44%Sell
Based on 9 Wall street analysts offering stock ratings for Inogen Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
5
5
7
Sell
4
4
3

Analyst Forecast

What analysts predicted

Downside of 8.32%

Current $7.09
Target $6.50

Company Financials

FY18Y/Y Change
Revenue
358.1M
↑ 43.57%
Net Income
51.8M
↑ 146.86%
Net Profit Margin
14.48%
↑ 6.06%
FY19Y/Y Change
Revenue
361.9M
↑ 1.07%
Net Income
21.0M
↓ 59.59%
Net Profit Margin
5.79%
↓ 8.69%
FY20Y/Y Change
Revenue
308.5M
↓ 14.77%
Net Income
-5.8M
↓ 127.82%
Net Profit Margin
-1.89%
↓ 7.68%
FY21Y/Y Change
Revenue
358.0M
↑ 16.05%
Net Income
-6.3M
↑ 8.65%
Net Profit Margin
-1.77%
↑ 0.12%
FY22Y/Y Change
Revenue
377.2M
↑ 5.37%
Net Income
-83.8M
↑ 1222.79%
Net Profit Margin
-22.21%
↓ 20.44%
FY23Y/Y Change
Revenue
315.7M
↓ 16.32%
Net Income
-102.4M
↑ 22.3%
Net Profit Margin
-32.46%
↓ 10.25%
Q3 FY22Q/Q Change
Revenue
105.4M
↑ 1.95%
Net Income
-9.5M
↑ 176.18%
Net Profit Margin
-9.02%
↓ 5.69%
Q4 FY22Q/Q Change
Revenue
88.1M
↓ 16.41%
Net Income
-56.6M
↑ 495.52%
Net Profit Margin
-64.26%
↓ 55.24%
Q1 FY23Q/Q Change
Revenue
72.2M
↓ 18.08%
Net Income
-20.3M
↓ 64.05%
Net Profit Margin
-28.2%
↑ 36.06%
Q2 FY23Q/Q Change
Revenue
83.6M
↑ 15.9%
Net Income
-9.8M
↓ 51.71%
Net Profit Margin
-11.75%
↑ 16.45%
Q3 FY23Q/Q Change
Revenue
84.0M
↑ 0.4%
Net Income
-45.7M
↑ 365.29%
Net Profit Margin
-54.45%
↓ 42.7%
Q4 FY23Q/Q Change
Revenue
75.9M
↓ 9.61%
Net Income
-26.6M
↓ 41.92%
Net Profit Margin
-34.99%
↑ 19.46%
FY18Y/Y Change
Total Assets
375.9M
↑ 36.65%
Total Liabilities
65.5M
↑ 36.32%
FY19Y/Y Change
Total Assets
447.3M
↑ 19.01%
Total Liabilities
102.7M
↑ 56.88%
FY20Y/Y Change
Total Assets
461.9M
↑ 3.24%
Total Liabilities
112.2M
↑ 9.26%
FY21Y/Y Change
Total Assets
489.5M
↑ 5.99%
Total Liabilities
119.3M
↑ 6.29%
FY22Y/Y Change
Total Assets
405.0M
↓ 17.26%
Total Liabilities
107.6M
↓ 9.77%
FY23Y/Y Change
Total Assets
326.2M
↓ 19.47%
Total Liabilities
121.4M
↑ 12.77%
Q3 FY22Q/Q Change
Total Assets
469.6M
↓ 0.1%
Total Liabilities
118.7M
↑ 4.59%
Q4 FY22Q/Q Change
Total Assets
405.0M
↓ 13.74%
Total Liabilities
107.6M
↓ 9.35%
Q1 FY23Q/Q Change
Total Assets
385.7M
↓ 4.78%
Total Liabilities
104.4M
↓ 3.03%
Q2 FY23Q/Q Change
Total Assets
374.4M
↓ 2.94%
Total Liabilities
99.6M
↓ 4.6%
Q3 FY23Q/Q Change
Total Assets
343.7M
↓ 8.19%
Total Liabilities
113.1M
↑ 13.55%
Q4 FY23Q/Q Change
Total Assets
326.2M
↓ 5.09%
Total Liabilities
121.4M
↑ 7.35%
FY18Y/Y Change
Operating Cash Flow
60.0M
↓ 0.85%
Investing Cash Flow
-25.0M
↑ 2.19%
Financing Cash Flow
18.3M
↑ 30.65%
FY19Y/Y Change
Operating Cash Flow
40.6M
↓ 32.32%
Investing Cash Flow
-44.1M
↑ 76.48%
Financing Cash Flow
4.9M
↓ 73.06%
FY20Y/Y Change
Operating Cash Flow
37.0M
↓ 8.82%
Investing Cash Flow
-25.6M
↓ 41.8%
Financing Cash Flow
2.1M
↓ 58.08%
FY21Y/Y Change
Operating Cash Flow
23.6M
↓ 36.15%
Investing Cash Flow
-14.6M
↓ 42.88%
Financing Cash Flow
15.0M
↑ 626.04%
FY22Y/Y Change
Operating Cash Flow
-37.5M
↓ 258.81%
Investing Cash Flow
-10.9M
↓ 25.73%
Financing Cash Flow
380.0K
↓ 97.47%
Q3 FY22Q/Q Change
Operating Cash Flow
-9.5M
↓ 271.45%
Investing Cash Flow
-4.8M
↓ 197.56%
Financing Cash Flow
701.0K
↓ 794.06%
Q4 FY22Q/Q Change
Operating Cash Flow
-15.5M
↑ 63.26%
Investing Cash Flow
-6.9M
↑ 46.04%
Financing Cash Flow
-112.0K
↓ 115.98%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.3M
↓ 59.3%
Investing Cash Flow
-17.1M
↑ 146.4%
Financing Cash Flow
559.0K
↓ 599.11%
Q2 FY23Q/Q Change
Operating Cash Flow
4.0M
↓ 163.96%
Investing Cash Flow
-540.0K
↓ 96.84%
Financing Cash Flow
-33.0K
↓ 105.9%

Technicals Summary

Sell

Neutral

Buy

Inogen Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inogen Inc
Inogen Inc
1.61%
48.5%
-45.28%
-88.94%
-91.17%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inogen Inc
Inogen Inc
NA
NA
3.48
-2.5
-0.41
-0.11
NA
8.78
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inogen Inc
Inogen Inc
Hold
$161.7M
-91.17%
NA
-32.46%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • BlackRock Inc

    9.60%

  • Camber Capital Management LLC

    8.57%

  • Brown Capital Management, LLC

    6.69%

  • Vanguard Group Inc

    5.82%

  • Morgan Stanley - Brokerage Accounts

    4.45%

  • Ameriprise Financial Inc

    4.11%

Corporate Announcements

  • Inogen Inc Earnings

    Inogen Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take

Organization
Inogen Inc
Employees
834
CEO
Mr. Jason Somer
Industry
Health Technology

Discover More

FAQs